Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.64 |
| ▸ | NPC1 | O15118 | 8/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17464244 | 0.79 | DHODH (0.56) | RAB9ANPC1L3MBTL1MEN1KMT2A | |
| SCHEMBL20018152 | 0.76 | ALDH1A1 (0.68) | RAB9ANPC1L3MBTL1PPARGMEN1 | |
| SCHEMBL1715306 | 0.75 | POLB (0.54) | RAB9ANPC1PTGS2L3MBTL1KMT2A | |
| SCHEMBL18160386 | 0.74 | MEN1 (0.69) | RAB9APPARGMEN1KMT2ALMNA | |
| SCHEMBL7956547 | 0.74 | RAB9A (0.68) | RAB9ANPC1PTGS2KMT2AKDM4E | |
| SCHEMBL20872521 | 0.73 | RAB9A (0.71) | RAB9ANPC1PTGS2MEN1KMT2A | |
| SCHEMBL2868817 | 0.73 | NPC1 (0.64) | RAB9ANPC1PTGS2ATML3MBTL1 | |
| Benzene SCHEMBL28942515 | 0.73 | RAB9A (0.71) | RAB9ANPC1PTGS2MEN1KMT2A | |
| SCHEMBL16687348 | 0.73 | KMT2A (0.54) | RAB9ANPC1L3MBTL1MEN1KMT2A | |
| SCHEMBL28893760 | 0.72 | NPC1 (0.65) | RAB9ANPC1PTGS2ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879887-B2 | such as 2-(4-chloro-3-hydroxyphenylamino)-N-(6H-pyrazolo[4',3':3,4]benzo[1,2-d]thiazol-2-yl)-acetamide, having antitumor activity, particularly dual inhibitory activity on Aurora kinase and cyclin-dependent kinase (CDK), and are useful for cell proliferative diseases such as cancer | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20090275623-A1 | ALPHA-AMINO ACID DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-2045253-A1 | a-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT | Nissan Chemical Industries, Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275623-A1 | ALPHA-AMINO ACID DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | CCNA1, AURKA, CDK1 | RAB9A 3986/4885NPC1 3238/4885PTGS2 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.